Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
网页2022年7月20日 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed...
FDA approves pembrolizumab for high-risk early-stage triple …
网页On July 26, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy...
FDA approves pembrolizumab as adjuvant treatment for non …
网页On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a...
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
网页2021年7月27日 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell …
网页2023年6月3日 · Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major...
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab …
网页2023年12月15日 · The overall survival benefit seen in the EV-302 trial demonstrates the potential for PADCEV in combination with pembrolizumab to impact first-line treatment of patients with locally advanced or metastatic urothelial carcinoma.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
网页2021年5月5日 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as …
Neoadjuvant Pembrolizumab Improves Event-Free Survival in …
网页2021年8月10日 · The latest analysis of the pivotal phase III KEYNOTE-522 trial demonstrated significant improvements in clinical outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone as a neoadjuvant/adjuvant treatment of triple-negative breast cancer. 1 This is the first large, randomized, phase III trial to report a statistically significant ...
Pembrolizumab for Advanced Triple-Negative Breast Cancer
网页2022年8月9日 · Adding the immunotherapy drug pembrolizumab (Keytruda) to chemotherapy can help some patients with advanced triple-negative breast cancer live longer than if they received chemotherapy alone, new results from a clinical trial show.
Pembrolizumab in the Treatment of Breast Cancer
网页2022年7月20日 · In this issue of the Journal, Cortes et al. 1 report that pembrolizumab — a breakthrough therapeutic treatment for patients with advanced triple-negative breast cancer — combined with...